MSB Trading - 2020, page-4634

https://kalkinemedia.com/au/news/mesoblast-receives-fda-green-flag-for-covid-19-drug-application-share-price-skyrockets35-per-cent

There are a few health sector companies that generated profitsby challenging the crisis of coronavirus in a commercial sense, and these stocks are catching investors’ eyes these days amid the COVID-19 outbreak. The profitable Australian healthcare sector often grabs the attention of investorswith the potential of delivering significant earnings and returns.

Numerous variables are accountable for increasing investors’concern in the healthcare sector, including new drug discoveries, Food and Drug Administration (FDA) approvals, demographics, patents and patent application and ongoing clinical studies and more.

The approval process from the FDA is an essential aspect that provides a decent impression on the fate of any healthcare stock. In general, FDA approval indicates an increasing share price for the Company. However, investors should consider each Company and each approval separately.

One healthcare sector player Mesoblast Limited is focused on achieving its established objectives and received approvals from the FDA for its drug candidates. Moreover, it is noteworthy thaton 6 April 2020, Mesoblast received an IND application approval for using Remestemcel-L in COVID-19 patients for treating acute respiratory distress syndrome (ARDS).

Let us deep dive and talk about the recent updates of the ASX-listed, regenerative medicine Company, Mesoblast.

Mesoblast Limited’s (ASX:MSB) share price up by ~35 per cent